Accessibility Menu
BriaCell Therapeutics logo

BriaCell Therapeutics(TSX) BCT

Market CapCA$48.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 YearN/A
1 Year-51%
1 Month+6%
CA$5.16
-8.19%
-0.46Today
BriaCell Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 5.162026-08-27
BriaCell Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.84%CAD 5.482026-08-20
1 month+6.17%CAD 4.862026-07-28
3 month+2.58%CAD 5.032026-05-29
Year to date-47.35%CAD 9.802025-12-31
1 year-50.86%CAD 10.502025-08-27
Since inception-99.96%CAD 13,050.132014-12-03

BriaCell Therapeutics Financials at a Glance

Market Cap

CA$48.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.65M

EPS (TTM)

-CA$16.87

P/E Ratio

-0.33

Dividend

CA$0.00

Beta (Volatility)

1.10 (Average)

Price

CA$5.16

Volume

18,436

Open

CA$5.45

Previous Close

CA$5.16

Daily Range

CA$5.06 - CA$5.45

52-Week Range

CA$3.68 - CA$20.40

Estimated Earnings Date

Mar 10, 2026

BCT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. The primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, evaluated in combination with the investigational immunotherapy retifanlimab.

Products and Services
  • Bria-IMT: Whole-cell cancer vaccine in clinical trials
  • Bria-OTS: Personalized immunotherapy for advanced breast cancer
  • BriaDx: Diagnostic test for determining patients' HLA types
Growth Outlook
  • Strong pipeline with multiple innovative therapies in development
  • Collaboration with Incyte Corporation enhances research capabilities
  • Partnership with the National Cancer Institute for preclinical studies
Financial Highlights
  • Recent quarterly net income of -$7.2 million, reflecting ongoing R&D investments
  • Cash and short-term investments total approximately $22.8 million
  • Current ratio of 7.07 indicates strong liquidity position
BriaCell Therapeutics Corp. is positioned in the biotechnology sector, focusing on developing immune-based therapies for cancer treatment. The company’s lead product, Bria-IMT, is currently in clinical trials, showcasing its commitment to advancing cancer therapies. The collaboration with Incyte Corporation and the National Cancer Institute signifies a strategic approach to enhance research and development efforts. Financially, BriaCell has a robust liquidity position, with significant cash reserves to support ongoing research and development activities. The current ratio of 7.07 indicates a strong ability to meet short-term obligations, which is crucial for a company in the clinical trial phase. Despite recent net income losses, the investments in research and development are essential for long-term growth and innovation in the competitive biotechnology landscape. Overall, BriaCell Therapeutics Corp. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the field of immuno-oncology. The company's innovative pipeline and strategic collaborations may position it favorably for future growth and success in the market.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17

CEO

William V. Williams, MD

Website

www.briacell.com

Headquarters

West Vancouver, BC V7T 2X1, CA

BCT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-147.92%

Return on Capital

-153.48%

Return on Assets

-113.23%

Earnings Yield

-3.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$48.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.70M

Volume

18.44K

Avg. Volume

6.67K

Financials (TTM)

Gross Profit

-$26.59K

Operating Income

-$32.01M

EBITDA

-$31.48M

Operating Cash Flow

-$30.88M

Capital Expenditure

-$129.18K

Free Cash Flow

-$31.01M

Cash & ST Invst.

$22.80M

Total Debt

$0.00

BriaCell Therapeutics Performance Analysis

BriaCell Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 0N/A
20232023-07-31USD 0N/A
20242024-07-31USD 0N/A
20252025-07-31USD 0N/A
BriaCell Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31N/A
Q12025-10-31N/A
Q22026-01-31N/A
Q32026-04-30N/A
BriaCell Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -329.76N/A
20232023-07-31USD -261.61-20.7%
20242024-07-31USD -59.36-77.3%
20252025-07-31USD -86.7346.1%
BriaCell Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-3173.9%
Q12025-10-31-1.6%
Q22026-01-3140.7%
Q32026-04-3061.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

CA$48.89MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.88M

N/A

Employees

17

N/A

Net Income

-$7.16M

-16.9%

EBITDA

-$7.17M

-16.4%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$22.80M

+83.0%

Total Debt

$0.00

N/A

Accounts Receivable

$2.59M

+11.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.13%

N/A

Return on Invested Capital

-1.36%

N/A

Free Cash Flow

-$7.21M

-0.6%

Operating Cash Flow

-$7.08M

+1.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBX.TOMicrobix Biosystems Inc.
CA$0.32+4.92%
RVX.TOResverlogix Corp.
CA$0.10-5.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$227.98+0.09%
INTCIntel
$92.09+0.04%
BITOProShares Trust - ProShares Bitcoin ETF
$10.78+0.02%
ONDSOndas
$8.75+0.06%

Questions About BCT

What is the current price of BriaCell Therapeutics?

BriaCell Therapeutics is trading at CA$5.16 per share.

What is the 52-week range for BriaCell Therapeutics?

Over the past 52 weeks, BriaCell Therapeutics has traded between CA$3.68 and CA$20.40.

How much debt does BriaCell Therapeutics have?

As of the most recent reporting period, BriaCell Therapeutics reported total debt of $0.00.

How much cash does BriaCell Therapeutics have on hand?

BriaCell Therapeutics reported $9.36M in cash and cash equivalents in its most recent financial results.

What is BriaCell Therapeutics’s dividend yield?

BriaCell Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services